Central Retinal Vein OcclusionMANAGEMENT

OPHTHALMOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

618 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Acute angle-closure glaucoma Central retinal artery occlusion Central Retinal Vein Occlusion Chemical eye injury Corneal abrasion Corneal ulcer Endophthalmitis Globe rupture Herpes zoster ophthalmicus Hyphema Iritis-Uveitis Ocular foreign body Optic Neuritis Orbital cellulitis Orbital Floor Fracture (Blowout)Posterior vitreous detachment Retinal detachment Retrobulbar hematoma and orbital compartment syndrome Vitreous Hemorrhage

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp36

Immediate priorities

›Vision-threatening emergency recognition

›Acute painless unilateral vision loss — ophthalmology consult same day or emergently

›Time from onset to treatment affects visual prognosis

›Ischemic CRVO — risk of neovascular glaucoma within 15 months

›Bilateral CRVO — urgent systemic workup

›Hyperviscosity syndrome concern

›Multiple myeloma or lymphoma

›Neovascular glaucoma presentation

›Eye pain with red eye after initial painless vision loss

›Elevated IOP with rubeosis iridis

›Emergent ophthalmology for IOP-lowering and PRP

Monitoring and targets

›Ocular monitoring priorities

›Visual acuity at presentation — documents baseline and guides classification

›VA >= 20/200 suggests non-ischemic CRVO

›VA < 20/200 suggests ischemic CRVO

›IOP measurement in all patients

›Elevated IOP — glaucoma risk factor and complication marker

›Repeat after dilation if neovascular glaucoma concern

›RAPD assessment — correlates with ischemia severity

›Present RAPD — strong predictor of neovascularization risk

›Absent RAPD — favors non-ischemic type

›Systemic monitoring

›Blood pressure — hypertension present in majority of CRVO patients

›Target SBP < 130 mmHg per cardiovascular risk guidelines

›Glucose — undiagnosed diabetes as precipitant

›Cardiovascular event risk — RR 1.45 for stroke, RR 1.26 for MI

02History/hx61

Presentation pattern

›Core vision symptoms

›Sudden painless unilateral decrease in vision

›Often noticed upon waking or when fellow eye covered

›Range from mild blurring to counting fingers or worse

›Onset timing

›Acute onset — hours to days

›Some patients present late after developing complications

›Visual field loss

›Central scotoma or diffuse field defect

›Inferior field loss from superior CRVO quadrant involvement

›Associated symptoms

›Floaters — vitreous hemorrhage from neovascularization

›New onset floaters after initial vision loss — complication marker

›Eye pain — absent at onset in typical CRVO

›Pain developing later — neovascular glaucoma

›Acute pain with red eye — urgent IOP measurement required

›Photopsias or curtain-like field loss — absent in CRVO, suggests retinal detachment

›Reduced depth perception

Risk factors

›Systemic risk factors

›Hypertension — strongest modifiable systemic risk factor

›Present in majority of CRVO patients

›Arteriovenous crossing compression mechanism

›Diabetes mellitus

›Endothelial dysfunction and hypercoagulability

›Compound risk with hypertension

›Dyslipidemia and atherosclerosis

03Physical Exam/exam50

Ocular examination

›Visual acuity — document best corrected

›VA >= 20/200 — non-ischemic CRVO likely

›80% of non-ischemic patients achieve VA >= 20/100 at 1 year

›VA < 20/200 — ischemic CRVO likely

›Only 12% achieve VA >= 20/100 at 1 year

›Pupillary examination

›Relative afferent pupillary defect (RAPD)

›Key finding correlating with ischemia severity

›Predicts neovascularization risk

›Absent or mild RAPD favors non-ischemic type

›IOP measurement — before dilation

›Elevated IOP — pre-existing glaucoma or neovascular glaucoma

›Asymmetric IOP — ocular ischemic syndrome consideration

Anterior segment examination

›Slit-lamp biomicroscopy

›Iris neovascularization (rubeosis iridis)

›Fine vessels at pupillary border extending to iris surface

›Approximately 25% of CRVO patients develop iris neovascularization

›Precursor to neovascular glaucoma

›Corneal edema — elevated IOP marker

›Anterior chamber depth and angle assessment

›Gonioscopy — perform before dilation in ischemic CRVO

›Angle neovascularization — precedes iris neovascularization

›Essential to detect before neovascular glaucoma develops

›Repeat at each follow-up visit in ischemic CRVO

Fundoscopic examination

›Classic CRVO findings on dilated fundoscopy

04Differential Diagnosis/ddx42

Vision-threatening diagnoses

›Ocular vascular emergencies

›Central retinal artery occlusion (CRAO)

›ICD-10 H34.1

›Painless vision loss but fundus shows pale ischemic retina with cherry-red spot at fovea

›No diffuse hemorrhages — key distinguishing feature

›Branch retinal vein occlusion (BRVO)

›ICD-10 H34.83

›Hemorrhages in one quadrant only — not all four quadrants

›Sector of dilated veins corresponds to occluded branch

›Ocular ischemic syndrome — carotid occlusive disease

›Dilated veins but typically low-pressure retinopathy

›Dot-blot hemorrhages in midperiphery

›Carotid bruit or reduced pulsation

Retinal and optic nerve mimics

›Structural and inflammatory causes

›Papilledema — bilateral disc edema

›ICD-10 H47.10

›Normal VA initially

›Associated with headache and elevated ICP

›Bilateral finding — key differentiator from CRVO

›Anterior ischemic optic neuropathy (AION)

›ICD-10 H47.01

›Disc edema with altitudinal field defect

›No diffuse retinal hemorrhages

›Papillophlebitis — CRVO variant in young patients 20–40 years

›Prominent disc swelling

›Generally good prognosis but 20% have substantial vision loss

05Laboratory Tests/lt41

Routine labs — all CRVO patients

›Cardiovascular risk assessment

›Fasting glucose and HbA1c

›Undiagnosed diabetes in substantial proportion

›HbA1c reflects 3-month glycemic control

›Lipid panel

›LDL, HDL, total cholesterol, triglycerides

›Dyslipidemia as modifiable risk factor

›Complete blood count with differential

›Polycythemia — hyperviscosity from elevated red cell mass

›Thrombocytosis — thrombotic risk

›Leukemia — infiltrative cause of venous occlusion

›BMP or CMP — renal function and electrolytes

›Renal disease associated with cardiovascular risk

›Medication dosing considerations

›Blood pressure measurement — systemic, both arms

Selective labs — younger patients and bilateral CRVO

›Thrombophilia workup — age younger than 50, bilateral CRVO, no traditional risk factors

›Homocysteine level

›Most consistently associated thrombophilia in CRVO

›Hyperhomocysteinemia treatable with folate, B6, B12

›Antiphospholipid antibodies

›Anticardiolipin IgG and IgM

›Anti-beta-2 glycoprotein I

›Lupus anticoagulant

›Protein C activity

›Protein S activity

›Antithrombin III activity

06Diagnostic Tests/dt66

Scoring Systems

›Ischemic vs non-ischemic classification — critical prognostic distinction

›Non-ischemic CRVO features

›Approximately 80% of presentations

›VA usually >= 20/200

›Absent or mild RAPD

›Mild-moderate scattered hemorrhages

›Few cotton-wool spots

›FFA non-perfusion < 10 disc areas

›Neovascular glaucoma risk rare

›Final VA >= 20/100 in 83%

›Ischemic CRVO features

›Approximately 20% of presentations

›VA usually < 20/200

›RAPD present

›Large confluent hemorrhages

›Multiple cotton-wool spots

›FFA non-perfusion >= 10 disc areas

›Neovascular glaucoma risk approximately 23% within 15 months

›Final VA >= 20/100 in only 12%

›Conversion risk — 25–34% of non-ischemic convert to ischemic within 3 years

MRI

›MRI ocular and orbital indications

›Limited acute utility for CRVO diagnosis

›Not first-line imaging modality

›Availability and time constraints

›Problem-solving indications

›Orbital or optic nerve pathology suspected

07Disposition/dispo23

Ophthalmology referral and admission

›Emergency ophthalmology indications

›Neovascular glaucoma — same-day emergency

›Eye pain with elevated IOP and rubeosis iridis

›Urgent IOP reduction and PRP planning

›Acute vision loss onset within hours — urgent same-day assessment

›Intravitreal injection consideration

›Vitreous hemorrhage obscuring fundus — same-day

›Urgent outpatient ophthalmology — within 24–48 hours

›Confirmed CRVO with VA > 20/200 and stable IOP

›Macular edema requiring OCT and injection planning

›Ischemic CRVO — frequent follow-up schedule

Systemic workup and follow-up disposition

›Internal medicine or primary care follow-up

›Risk factor optimization — hypertension, diabetes, dyslipidemia

›Blood pressure control — strongest modifiable risk factor

›Glucose control

›Cardiovascular risk reduction plan

›CRVO associated with RR 1.45 for stroke, RR 1.26 for MI, RR 1.53 for heart failure

›AF workup follow-up — Holter monitoring if ECG screen negative

›7-day Holter doubles AF detection rate over baseline ECG

›Hospital admission indications — uncommon for isolated CRVO

›Hyperviscosity crisis — acute systemic emergency

›Bilateral CRVO with systemic decompensation

›Concurrent acute cardiovascular event

08Treatment/t81

Intravitreal anti-VEGF therapy — first-line

›Anti-VEGF agents — FDA-approved for CRVO-associated macular edema

›Ranibizumab (Lucentis) intravitreal injection

›0.5 mg per 0.05 mL intravitreal injection

›Monthly injections initially

›As-needed or treat-and-extend after loading phase

›FDA-approved for CRVO macular edema

›Aflibercept (Eylea) intravitreal injection

›2 mg per 0.05 mL intravitreal injection

›Monthly for 6 months then as-needed

›FDA-approved for CRVO macular edema

›Faricimab-svoa (Vabysmo) intravitreal injection

›6 mg per 0.05 mL intravitreal injection

›Dual VEGF-A and Ang-2 inhibition

›FDA-approved for CRVO macular edema

›Bevacizumab (Avastin) intravitreal injection — off-label

›1.25 mg per 0.05 mL intravitreal injection

›Demonstrated efficacy — commonly used off-label

›Lower cost alternative

›Anti-VEGF treatment principles

›Initiated by ophthalmology — not emergency department role

›Reduces macular edema and improves visual acuity

›Requires ongoing monitoring and retreatment

Intravitreal corticosteroids — second-line

›Dexamethasone intravitreal implant (Ozurdex)

›0.7 mg sustained-release biodegradable implant

›Duration of effect approximately 3–6 months

›Injected in office procedure

›Indications

›Anti-VEGF inadequate response

›Pseudophakic patients — lower cataract risk

›Patients with cardiovascular contraindications to anti-VEGF

›Adverse effects

›Secondary glaucoma — IOP elevation in 16–33%

›Cataract formation — significant in phakic patients

›Triamcinolone acetonide intravitreal injection — alternative

›4 mg per 0.1 mL intravitreal injection

›Off-label use

›Higher IOP elevation risk than dexamethasone implant

›Similar adverse effect profile to dexamethasone implant

Laser photocoagulation

›Panretinal photocoagulation (PRP)

›Indications — neovascularization present

›Iris neovascularization (rubeosis iridis)

›Retinal neovascularization

›Angle neovascularization on gonioscopy

›Mechanism — ablates ischemic retina reducing VEGF stimulus

›Performed by ophthalmology — typically as urgent or semi-urgent procedure

›Does not improve visual acuity — prevents neovascular glaucoma

›Grid laser photocoagulation — largely superseded by anti-VEGF

›Historical treatment for macular edema

›Less effective than intravitreal anti-VEGF for visual acuity improvement

Systemic risk factor treatment

›Blood pressure management

›Antihypertensive therapy optimization

›Target SBP < 130 mmHg for cardiovascular risk reduction

›Coordinate with primary care or internal medicine

›Hypertension — strongest modifiable systemic risk factor for CRVO

›Antiplatelet therapy

›Aspirin — may be considered for overall cardiovascular risk reduction

›No specific role in preventing CRVO recurrence

›No proven benefit for CRVO treatment

›No role for systemic anticoagulation in routine CRVO management

›Hyperhomocysteinemia treatment

›Folic acid supplementation

›1–5 mg daily PO

›Vitamin B12 supplementation if deficient

›Pyridoxine (B6) supplementation

›Lipid-lowering therapy — if dyslipidemia present

›Statin therapy for cardiovascular risk reduction

›Target LDL based on cardiovascular risk category

IOP lowering — neovascular glaucoma management

›Topical IOP-lowering agents — initiated by ophthalmology

›Timolol 0.5% ophthalmic solution

›1 drop twice daily

›Avoid in severe asthma, COPD, heart block

›Brimonidine 0.2% ophthalmic solution

›1 drop three times daily

›Avoid with MAOI use

›Dorzolamide or brinzolamide — topical carbonic anhydrase inhibitors

›1 drop two to three times daily

›Systemic IOP lowering — acute severe elevation

›Acetazolamide oral or IV

›250–500 mg PO or IV for acute IOP crisis

›Avoid in sulfonamide allergy

›Avoid in severe renal or hepatic disease

09Special Populations/sp73

Pregnancy

›Pregnancy-specific considerations

›CRVO in pregnancy — rare; associated with hypercoagulable state of pregnancy

›Increased clotting factor levels

›Reduced protein S activity during pregnancy

›Third trimester and postpartum highest risk period

›Thrombophilia screening more aggressively indicated in pregnant CRVO patients

›Antiphospholipid syndrome — recurrent pregnancy loss association

›Inherited thrombophilias with pregnancy complication risk

›Imaging in pregnancy

›Fundoscopy and OCT — safe in pregnancy

›No radiation exposure

›FFA — avoid if possible; fluorescein safety in pregnancy not established

›CT — avoid unless life-threatening indication

›MRI without gadolinium — preferred over CT when cross-sectional imaging needed

›Treatment modifications

›Anti-VEGF intravitreal injections — use with caution

›Theoretical systemic VEGF inhibition risk to fetus

›Decision in consultation with maternal-fetal medicine and ophthalmology

›Corticosteroid intravitreal implants — limited pregnancy safety data

›Anticoagulation — heparin or LMWH if antiphospholipid syndrome or major thrombophilia

›Warfarin — avoid in first trimester and near delivery

›Blood pressure management

›Avoid ACE inhibitors and ARBs — teratogenic

›Labetalol, methyldopa, nifedipine — preferred antihypertensives

Geriatric

›Older adult considerations

›Higher prevalence of traditional risk factors

›Hypertension most prevalent

›Diabetes and dyslipidemia common

›Lower threshold for cardiovascular workup

›ECG and ambulatory monitoring

›Echocardiography if multiple risk factors

›Thrombophilia screening — low yield in older adults with traditional risk factors

›Meta-analysis: inherited thrombophilia prevalence similar to healthy subjects in typical older CRVO patients

›Medication considerations

›Polypharmacy interactions with systemic treatments

›Aspirin with anticoagulants — bleeding risk review

›Antihypertensive interactions

›Anti-VEGF intravitreal injections — appropriate for older adults

›Procedure tolerance and positioning considerations

›Caregiver support for follow-up visits

›IOP-lowering drops — beta-blocker caution

›Timolol systemic absorption — bradycardia and bronchospasm risk

›Prefer selective agents in cardiac disease

›Disposition considerations

›Falls risk assessment — sudden visual loss in older adults

›Depth perception reduction increases fall risk

›Mobility aids and home safety review

›Driving cessation counseling

›Unilateral vision loss may affect visual fields below licensing threshold

Pediatrics

›Pediatric CRVO — rare presentation

›Underlying systemic disease typically present

›Congenital heart disease

›Hematologic malignancy

›Inherited thrombophilia — factor V Leiden, protein C/S deficiency

›Thorough systemic evaluation mandatory

›Hematology consultation — thrombophilia workup

›Cardiology consultation if cardiac disease suspected

›Pediatric workup

›Complete thrombophilia panel in all pediatric CRVO

›Higher pretest probability of identifiable cause than adults

›Homocysteine, antiphospholipid antibodies, protein C/S, factor V Leiden

›Leukemia and lymphoma screen

›CBC with differential

›Peripheral smear

›Inflammatory markers — vasculitis evaluation

›Treatment in children

›Anti-VEGF dosing — extrapolated from adult data

›No established pediatric dosing protocols

›Ophthalmology-directed management

›Anticoagulation — if thrombophilia identified

›Hematology-guided anticoagulation

›Weight-based LMWH dosing — enoxaparin 1 mg/kg subcutaneous twice daily

›Adjust by anti-Xa monitoring

10Background/b83

Epidemiology

›Incidence and prevalence

›Second most common retinal vascular disorder after diabetic retinopathy

›Incidence approximately 0.8 per 1000 persons per year

›Prevalence approximately 0.1–0.2% of general population

›Distribution by type

›Non-ischemic CRVO — approximately 80% of presentations

›Ischemic CRVO — approximately 20% of presentations

›Age distribution

›Predominantly age 50 and older

›Mean age of onset in seventh decade

›Young patients (age < 50) — 58% have non-traditional risk factor identified

›Systemic associations and mortality

›Cardiovascular mortality risk

›Increased risk of stroke — RR 1.45

›Increased risk of MI — RR 1.26

›Increased risk of heart failure — RR 1.53

›Fellow eye risk — 1% per year risk of contralateral CRVO

›Conversion risk — 25–34% of non-ischemic CRVO converts to ischemic within 3 years

Pathophysiology

›Mechanism of venous obstruction

›Thrombosis at lamina cribrosa level

›Central retinal vein passes through lamina cribrosa alongside central retinal artery

›Arteriovenous crossing compression from arterial pulsation

›Atherosclerotic arterial wall changes compress adjacent vein

›Virchow triad contribution

›Endothelial injury — hypertension, diabetes, atherosclerosis

›Stasis — hyperviscosity, glaucoma elevating venous resistance

›Hypercoagulability — thrombophilia, oral contraceptives, dehydration

›Downstream consequences

›Increased venous hydrostatic pressure

›Retinal hemorrhages — breakdown of vessel walls

›Macular edema — fluid accumulation in outer plexiform layer

›Cotton-wool spots — nerve fiber layer ischemia

›Retinal ischemia — ischemic type

›Non-perfusion of capillary bed

›Defined as >= 10 disc areas on FFA

›Upregulates retinal VEGF production

›VEGF-driven complications

›Retinal neovascularization

›Iris neovascularization — rubeosis iridis

›Neovascular glaucoma — angle closure from fibrovascular membrane

›Classification system

›Non-ischemic CRVO — perfused type

›< 10 disc areas non-perfusion on FFA

›Lower VEGF load

›Generally better prognosis

›Ischemic CRVO — non-perfused type

›>= 10 disc areas non-perfusion on FFA

›High VEGF load drives neovascularization

›Neovascular glaucoma risk approximately 23% within 15 months

Therapeutic Considerations

›Anti-VEGF rationale

›VEGF is primary mediator of macular edema in CRVO

›Anti-VEGF directly reduces VEGF-driven vascular permeability

›Reduces macular edema and improves visual acuity

›Evidence basis — pivotal randomized controlled trials

›CRUISE trial — ranibizumab for CRVO macular edema

›COPERNICUS and GALILEO trials — aflibercept for CRVO

›Class I recommendation based on RCT evidence

›Ongoing treatment need — CRVO macular edema frequently recurs

›Treat-and-extend or as-needed protocols to reduce injection burden

›Natural history without treatment

›Non-ischemic CRVO — variable spontaneous resolution

›Some improvement over 12–18 months

›Macular edema persists in significant proportion without treatment

›Ischemic CRVO — poor untreated visual prognosis

›High risk of permanent visual loss from macular ischemia

›Neovascular glaucoma develops in 23% within 15 months if untreated

›Corticosteroid rationale

›Reduces inflammatory component of macular edema

›Downregulates multiple permeability mediators

›Effective in anti-VEGF non-responders

›Adverse effect trade-off

›IOP elevation requiring monitoring and treatment

›Cataract acceleration in phakic patients

›Monitoring protocol

›OCT — primary tool for macular edema quantification and treatment response

›Central subfield thickness measurement

›Repeat at each follow-up visit

›FFA — perfusion status and neovascularization screening

›Degree of non-perfusion guides treatment intensity

›Ischemic CRVO requires more frequent neovascularization screening

›Gonioscopy — angle neovascularization monitoring in ischemic CRVO

›Every 1–3 months in ischemic CRVO for first year

›PRP triggered by any neovascularization detected

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Central Retinal Vein Occlusion — what you should know

›Your diagnosis — blockage of the main vein draining your retina

›This caused the sudden vision change you experienced

›The retina is the light-sensitive layer at the back of your eye

›Your follow-up appointment with an eye specialist is critically important

›Do not miss your ophthalmology appointment

›Eye injections or laser treatment may be needed to protect your vision

›Medications and eye drops

›Take all prescribed medications exactly as directed

›Use prescribed eye drops on schedule

›Do not skip doses — IOP control protects your eye

›Continue all blood pressure and diabetes medications

›Risk factor control at home

›Check blood pressure regularly if you have a home monitor

›Target below 130/80 mmHg

›Follow your diabetes management plan — check blood sugar as directed

›Eat a heart-healthy diet — DASH or Mediterranean style

›Stay well hydrated — avoid dehydration

›Do not smoke — smoking worsens vascular disease

›Activity and driving

›Do not drive until cleared by your eye doctor

›Vision loss in one eye may affect your visual field and depth perception

›Be careful with stairs and uneven surfaces — depth perception may be reduced

›Ask for help if needed at home

›Return to the emergency department immediately if

›Sudden eye pain — especially if your eye becomes red and painful

›This can mean increased eye pressure requiring urgent treatment

12References/r29

Guidelines and key sources

›Ophthalmology society guidelines

›American Academy of Ophthalmology Preferred Practice Pattern — Retinal Vein Occlusions

›Evidence-based guidance on classification, workup, and treatment

›Anti-VEGF as first-line for macular edema — Level I evidence

›Royal College of Ophthalmologists UK Guidelines — Retinal Vein Occlusion

›Systemic cardiovascular risk assessment recommendations

›Pivotal clinical trials

›CRUISE trial — ranibizumab for CRVO-associated macular edema

›Demonstrated superiority of anti-VEGF over sham injection

›COPERNICUS trial — aflibercept 2 mg for CRVO

›Monthly aflibercept superior to sham at 6 months

›GALILEO trial — aflibercept 2 mg for CRVO in European population

›Confirmed COPERNICUS findings in independent cohort

›Cardiovascular risk evidence

›Cardiovascular mortality and RVO — pooled analysis

›Stroke RR 1.45, MI RR 1.26, heart failure RR 1.53

›AF prevalence in RVO — 7-day Holter monitoring study

›AF prevalence 18.4% on prolonged monitoring vs 10.2% on baseline ECG

›Thrombophilia evidence

›Meta-analysis — thrombophilia prevalence in RVO vs healthy subjects

›Inherited thrombophilias not significantly increased in typical older patients

›Supports selective rather than routine thrombophilia screening

Coding references

›Diagnostic coding

›ICD-10 H34.81 — central retinal vein occlusion

›H34.811 — right eye

›H34.812 — left eye

Learn More: Central Retinal Vein Occlusion→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.